March 25, 2025 - 00:43
SOUTH SAN FRANCISCO, Calif., March 24, 2025—Quince Therapeutics, Inc., a late-stage biotechnology company focused on leveraging the potential of patients' own biology to address rare diseases, has announced significant updates regarding its development pipeline alongside its financial results for the fiscal year ending December 31, 2024.
The company has made notable strides in advancing its therapeutic candidates, emphasizing its commitment to innovation in the treatment of conditions that currently lack effective solutions. Key milestones achieved over the past year include successful clinical trials and the initiation of new studies aimed at expanding its therapeutic offerings.
Financially, Quince Therapeutics reported a robust performance, reflecting the investments made in research and development. The company is optimistic about its future prospects, as it continues to explore partnerships and collaborations that could enhance its market position. Overall, the updates signify a promising trajectory for Quince Therapeutics as it works to improve the lives of patients with rare diseases.
